ГЕНДЕРНЫЕ РАЗЛИЧИЯ В ПРОЯВЛЕНИИ ЛЕГОЧНОЙ ГИПЕРТЕНЗИИ. ВЛИЯНИЕ ЖЕНСКОГО ПОЛОВОГО ГОРМОНА ЭСТРАДИОЛА

Легочная гипертензия (ЛГ) — группа гетерогенных заболеваний, отличающихся своей этиологией и фенотипом, но объединенных основными симптомами заболевания — повышением артериального давления в малом круге кровообращения и гипертрофией правого желудочка сердца. Важной особенностью всех типов ЛГ является гендерная зависимость в проявлении этого заболевания. Согласно клиническим данным женская часть населения в большей степени подвержена ЛГ, что противоречит представлениям о протективном действии женского полового гормона. Это явление получило название эстрадиолового парадокса. В обзоре обсуждаются возможные механизмы гендерных различий в проявлении ЛГ, сравниваются экспериментальные данные, полученные на животных, с результатами клинических исследований, анализируются геномный и негеномный эффект действия эстрадиола на состояние сердечнососудистой системы, возможное участие метаболитов эстрадиола и механизмы гипертрофии правого желудочка сердца.

легочная гипертензия, гендерные различия, эстрадиол, эстрадиоловый парадокс, рецепторы к эстрадиолу, модели легочной гипертензии, гипоксическая форма легочной гипертензии, систолическое давление в правом желудочке сердца, гипертрофия

1. Ghataorhe P, Rhodes CJ, Harbaum L, Attard M, Wharton J, Wilkins MR. Pulmonary arterial hypertension — progress in understanding the disease and prioritizing strategies for drug development. J Intern Med. 2017;282(2):129–141. doi:10. 1111/joim.12623

2. Seyfarth HJ, Gille J, Sablotzki A, Gerlach, Malcharek M, Gosse A et al. Perioperative management of patients with severe pulmonary hypertension in major orthopedic surgery: experiencebased recommendations GMS Interdiscip Plast Reconstr Surg DGPW. 2015; 4: Doc03 doi:10.3205/iprs000062

3. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Pediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–75. doi:10. 1093/eurheartj/ehv317

4. Dweik RA, Rounds S, Erzurum SC, Archer S, Fagan K, Hassoun PM et al. An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med. 2014;189(3):345–55. doi:10.1164/rccm.201311–1954ST

5. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K et al. A global view of pulmonary hypertension. Lancet Respirat Med. 2016;4(4):306–22. doi:10.1016/S2213–2600 (15)00543–3

6. Чазова И. Е., Мартынюк Т. В., Авдеев С. Н., Волков А. В., Наконечников С. Н. Диагностика и лечение легочной гипертензии. Клинические рекомендации. М., 2013. 47 c. URL: http://mzdrav. rk.gov.ru/file/mzdrav_18042014_Klinicheskie_rekomendacii_ Legochnaja_gipertenzija.pdf [Chazova IE, Martynyuk TV, Avdeed SN, Volkov AV, NakonechnikovSN. Diagnostics and management of pulmonary hypertension. Clinical guidelines. M., 2013. 47 p. URL: http://mzdrav.rk.gov.ru/file/mzdrav_18042014_Klinicheskie_ rekomendacii_Legochnaja_gipertenzija.pdf].

7. Dunham-Snary KJ, Wu D, Sykes EA, Thakrar A,, Mewburn JD et al. Hypoxic pulmonary vasoconstriction: from molecular mechanisms to medicine. Chest. 2016; 151(1):181–192. doi: 10.1016/ j.chest.2016.09.001

8. Hussain A, Suleiman MS, George SJ, Loubani M, Morice A. Hypoxic pulmonary vasoconstriction in humans: tale or myth. Open Cardiovasc Med J. 2017;11:1–13. doi:10.2174/ 1874192401711010001

9. Post JM, Hume JR, Archer SL, Weir EK. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol. 1992;262(4 Pt 1): C882–890.

10. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012;122(12):4306–4313. doi:10. 1172/JCI60658

11. Tuder RM, Archer SL, Dorfmuller P, Erzurum SC, Guignabert C, Michelakis E. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl): D4–D12. doi:10.1016/j.jacc.2013.10.02

12. Tuder RM, Stacher E, Robinson J, Kumar R, Graham BB. Pathology of pulmonary hypertension. Clin Chest Med. 2013;34(4):639–650. doi:10.1016/j.ccm.2013.08.009

13. Кирова Ю. И. Влияние гипоксии на динамику содержания HIF-1α в коре головного мозга и формирование адаптации у крыс с различной резистентностью к гипоксии. Патол. физиол. и эксп. терапия.2012; N3:51–55. [Kirova YuI. Effect of hypoxia on dynamics of HIF-1α level in the cerebral cortex and development of adaptation in rats with different resistance to hypoxia. Pathophysiology and Experimental Therapy. 2012; (3):51–5. In Russian].

14. Кирова Ю. И., Германова Э. Л., Лукьянова Л. Д. Фенотипические особенности динамики содержания HIF-1α в неокортексе крыс при различных режимах гипоксии. Бюлл. эксп. биол. мед. 2012;154(12):681–686. [Kirova YuI, Germanova EL, Luk'ianova LD. Phenotypic characteristics of HIF1α level of the rat neocortical cells at different hypoxia modes. Bullettin of Experimental Biolology and Medicine. 2012;154(12):681–686. In Russian].

15. Santos-Ribeiro D, Mendes-Ferreira P, Maia-Rocha C, Adão R, Leite-Moreira AF, Brás-Silva C. Pulmonary arterial hypertension: Basic knowledge for clinicians, Arch Cardiovasc Dis. 2016;109(10):550–561.

16. Johns RA, Takimoto E, Meuchel LW, Elsaigh E, Zhang A, Heller N. Hypoxia-inducible factor 1α is a critical downstream mediator for hypoxia-induced mitogenic factor (FIZZ1/RELMα)induced pulmonary hypertension Arterioscler Thromb Vasc Biol. 2016;36(1):134–44.

17. Steven S, Oelze M, Brandt M, Ullmann E, Kröller-Schön S, Heeren T. Pentaerythritol tetranitrate in vivo treatment improves oxidative stress and vascular dysfunction by suppression of endothelin-1 signaling in monocrotaline-induced pulmonary hypertension. Oxid Med Cell Longev. 2017;2017:4353462. doi:10. 1155/2017/4353462.

18. Zeng X, Zhu L, Xiao R, Liu B, Sun M, Liu F et al. Hypoxiainduced mitogenic factor acts as a nonclassical ligand of calciumsensing receptor, therapeutically exploitable for intermittent hypoxia-induced pulmonary hypertension. Hypertension. 2017;69 (5):844–854. doi:10.1161/HYPERTENSIONAHA.116.08743

19. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008;117(13):1717– 1731. doi: 10.1161/ CIRCULATIONAHA.107.653584

20. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114(17):1883–1891.

21. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest 2010;137(2):376– 387. doi:10.1378/chest.09–1140

22. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Resp Crit Care Med. 2006;173(9): 1023–1030.

23. Kleiger RE., Boxer M, Ingham RE, Harrison DC. Pulmonary hypertension in patients using oral contraceptives. A report of six cases. Chest. 1976;69(2):143–147.

24. Sweeney L, Voelkel NF. Estrogen exposure, obesity and thyroid disease in women with severe pulmonary hypertension. Eur J Med Res. 2009;14(10):433–442.

25. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP et al. Alterations in estrogen metabolism: implications for higher penetrance of FPAH in females. Eur Respir J 2009;34(5): 1093–1099. doi:10.1183/09031936.00010409

26. Ventetuolo CE, Ouyang P, Bluemke DA, Tandri H, Barr RG, Bagiella E et al. Sex hormones are associated with right ventricular structure and function: the MESA-right ventricle study. Am J Respir Crit Care Med. 2011;183 5):659–667. doi:10.1164/rccm.201007– 1027OC

27. Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM. Sex and hemodynamics in pulmonary arterial hypertension. Eur Respir J. 2014;43(2):523–530. doi:10.1183/ 09031936.00027613

28. Beretta L, Caronni M, Origgi L, Ponti A, Santaniello A, Scorza R. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand J Rheumatol. 2006;35(6):468–471.

29. Scorza R, Caronni M, Bazzi S, Nador F, Beretta L, Antonioli R, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann NY Acad Sci. 2002;966:238–24.

30. Assaggaf H, Felty Q. Gender, Estrogen, and Obliterative Lesions in the Lung. Int J Endocrinol. 2017;2017:8475701. doi:10.1155/2017/8475701

31. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164–172.

32. Umar S, Rabinovitch M, Eghbali M. Estrogen paradox in pulmonary hypertension. Am J Respir Crit Care Med. 2012;186 (2): 125–131.

33. Смирнов А. Н. Элементы эндокринной регуляции. М.: ГЭОТАР-Медиа, 2006. 351 с. [Smirnov AN. Elements of endocrine regulation. M.: GEOTAR-Media, 2006. 351 p. In Russian].

34. Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H, Takagi Y. Localized expression of aromatase in human vascular tissues. Circ Res. 1999;84(11):1285–1291.

35. Kypreos KE, Zafirovic S, Petropoulou PI, Bjelogrlic P, Resanovic I, Traish A et al. Regulation of endothelial nitric oxide synthase and high-density lipoprotein quality by estradiol in cardiovascular pathology. J Cardiovasc Pharmacol Ther. 2014;19 (3):256–68.

36. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2029–2035. doi:10.1158/1055–9965. EPI-08–0262

37. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227(2):115–124.

38. Dubey RK, Tofovic SP, Jackson EK. Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther. 2004;308(2):403–409.

39. Parl FF, Dawling S, Roodi N, Crooke PS. Estrogen metabolism and breast cancer: a risk model. Ann NY Acad Sci 2009;1155:68–75.

40. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA. 1988;85(21):7831–7835.

41. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 2005;12(4):1071–1082.

42. Muti P, Westerlind K, Wu T, Grimaldi T, De Berry J 3rd, Schunemann H et al. Urinary estrogen metabolites and prostate cancer: a case-control study in the United States. Cancer Causes Control. 2002;13(10):947–955.

43. Tofovic SP, Zhang X, Jackson EK, Dacic S, Petrusevska G. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol. 2006;45(6):358–367.

44. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L. Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation. 2012;126(9):1087–1098. doi:10.1161/ CIRCULATIONAHA.111.062927

45. Fessel JP, Chen X, Frump A, Gladson S, Blackwell T, Kang C et al. Interaction between bone morphogenetic protein receptor

46. type 2 and estrogenic compounds in pulmonary arterial hypertension. Pulm Circ. 2013;3(3):564–577. doi:10.1086/674312

47. Yuan P, Wu WH, Gao L, Zheng ZQ, Liu D, Mei HY. Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, prostacyclin and endothelin-1 pathways. Eur Respir J. 2013;41 (5):1116–1125. doi:10.1183/09031936.00044112

48. Umar S, Iorga A, Matori H, Nadadur RD, Li J, Maltese F, et al. Estrogen rescues preexisting severe pulmonary hypertension in rats. Am J Respir Crit Care Med. 2011;184(6):715–723. doi:10.1164/ rccm.201101–0078OC

49. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87(3):905–931.

50. Murphy E. Estrogen signaling and cardiovascular disease. Circ Res. 2011;109(6):687–696. doi:10.1161/CIRCRESAHA.110.236687

51. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Genazzani AR. Genomic and non-genomic effects of estrogens on endothelial cells. Steroids. 2004;69(8–9):537–542.

52. Hsieh YC, Yu HP, Frink M, Suzuki T, Choudhry MA, Schwacha MG. G-protein-coupled receptor 30-dependent protein kinase A pathway is critical in nongenomic effects of estrogen in attenuating liver injury after trauma-hemorrhage. Am J Pathol. 2007;170(4):1210–1218.

53. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000;407(6803):538–541.

54. Hisamoto K, Ohmichi M, Kurachi H, Hayakawa J, Kanda Y, Nishio Y et al. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem. 2001;276(5):3459–3467.

55. Sherman TS, Chambliss KL, Gibson LL, Pace MC, Mendelsohn ME, Pfister SL et al. Estrogen acutely activates prostacyclin synthesis in ovine fetal pulmonary artery endothelium. Am J Respir Cell Mol Biol. 2002;26(5):610–616.

56. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297(6): L1013–L1032. doi:10.1152/ajplung. 00217.2009

57. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001;15(2):427–438.

58. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D,Smithson L et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation. 2009;120(20):1951–1960. doi:10.1161/CIRCULATIONAHA. 109.883843

59. Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, et al. A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol. 2012;302(10): L977–L991. doi:10.1152/ajplung.00362.2011

60. Baron RM, Choi AJ, Owen CA, Choi AM. Genetically manipulated mouse models of lung disease: potential and pitfalls. Am J Physiol Lung Cell Mol Physiol 2012;302(6): L485–L497. doi:10.1152/ajplung.00085.2011

61. McMurtry IF, Frith CH, Will DH. Cardiopulmonary responses of male and female swine to simulated high altitude. J Appl Physiol. 1973;35(4):459–462.

62. Rabinovitch M, Gamble WJ, Miettinen OS, Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol Heart Circ Physiol. 1981;240 (1): H62–H72.

63. Burton RR, Besch EL, Smith AH. Effect of chronic hypoxia on the pulmonary arterial blood pressure of the chicken. Am J Physiol. 1968;214(6):1438–1442.

64. Wetzel RC, Sylvester JT. Gender differences in hypoxic vascular response of isolated sheep lungs. J Appl Physiol. 1983;55(1 Pt 1):100–104.

65. Wetzel RC, Zacur HA, Sylvester JT. Effect of puberty and estradiol on hypoxic vasomotor response in isolated sheep lungs. J Appl Physiol.1984;56(5):1199–1203.

66. Fuchs KI, Moore LG, Rounds S. Pulmonary vascular reactivity is blunted in pregnant rats. J Appl Physiol. 1982;53 (3):703–707.

67. Moore LG, Reeves JT. Pregnancy blunts pulmonary vascular reactivity in dogs. Am J Physiol Heart Circ Physiol. 1980;239(3): H297–H301.

68. Earley S, Resta TC. Estradiol attenuates hypoxia-induced pulmonary endothelin-1 gene expression. Am J Physiol Lung Cell Mol Physiol. 2002;283(1): L86–L93.

69. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Weil B et al. Exogenous estrogen rapidly attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction. Shock. 2008;30(6):660–667. doi:10.1097/SHK.0b013e31816f239f

70. Lahm T, Patel KM, Crisostomo PR, Markel TA, Wang M, Herring C et al. Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Am J Physiol Endocrinol Metab. 2007;293(3): E865–E871.

71. Resta TC, Kanagy NL, Walker BR. Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am J Physiol Lung Cell Mol Physiol. 2001;280 (1):L88–L97.

72. Farhat MY, Chen MF, Bhatti T, Iqbal A, Cathapermal S, Ramwell PW. Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats. Br J Pharmacol. 1993;110(2):719–723.

73. Xu DQ, Luo Y, Liu Y, Wang J, Zhang B, Xu M, Wang YX. Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats. Respir Res. 2010; 11:182. doi:10.1186/1465–9921–11–182

74. Lahm T, Albrecht M, Fisher AJ, Selej M, Patel NG, Brown JA. 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med. 2012;185(9):965–80. doi:10.1164/rccm.201107–1293OC

75. Панькова Н. В., Артемьева М. М., Медведева Н. А. Влияние эстрадиола 17-бета на степень проявления гипоксической формы легочной гипертонии у самцов и самок крыс Вистар. Экспериментальная и клиническая фармакология. 2017;80 (1):9–13. [Pankova NV, Artemieva MM, Medvedeva NA. 17-beta estradiol effect on hypoxic lung hypertension level in male and female Wistar rats. Experimental and Clinical Pharmacology. 2017;80(1):9–13. In Russian].

76. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, Maclean MR. The serotonin transporter, gender, and 17-oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res. 2011;90(2):373–682. doi: 10.1093/cvr/cvq408

77. White K, Loughlin L, Maqbool Z, Nilsen M, McClure J, Dempsie Y et al. Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiol Genomics. 2011;43(8):417–437. doi:10.1152/physiolgenomics.00249.2010

78. Dempsie Y, Nilsen M, White K, Mair KM, Loughlin L, Ambartsumian N et al. Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Respir Res 2011;12:159. doi:10.1186/1465–9921–12–159

79. Dempsie Y, MacRitchie NA, White K, Morecroft I, Wright AF, Nilsen M. Dexfenfluramine and the oestrogenmetabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension. Cardiovasc Res. 2013;99(1):24–34. doi:10. 1093/cvr/cvt064

80. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferatoractivated receptor-gamma activation. Circulation.2007;115 (10):1275–1284.

81. Longcope C, Gorbach S, Goldin B, Woods M, Dwyer J, Morrill A. The effect of a low fat diet on estrogen metabolism. J Clin Endocrinol Metab. 1987;64(6):1246–1250.

82. Heresi GA, Aytekin M, Newman J, DiDonato J, Dweik RA. Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182(5):661–668. doi:10.1164/rccm.201001–0007OC

83. Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 2009;33(2):318–324. doi:10.1183/ 09031936.00000508

84. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179(9):835–842. doi:10.1164/rccm.200809–1472OC

85. Felty Q, Xiong WC, Sun D, Sarkar S, Singh KP, Parkash J et al. Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers. Biochemistry. 2005;44(18):6900– 6909.

86. Farha S, Asosingh K, Laskowski D, Hammel J, Dweik RA, Wiedemann HP, Erzurum SC. Effects of the menstrual cycle on lung function variables in women with asthma. Am J Respir Crit Care Med. 2009;180(4):304–310. doi:10.1164/rccm.200904–0497OC

87. Farha S, Asosingh K, Laskowski D, Licina L, Sekiguchi H, Losordo DW et al. Pulmonary gas transfer related to markers of angiogenesis during the menstrual cycle. J Appl Physiol. 2007;103 (5):1789–1795.